GlassScriptPhysician profile
Emmanuel Akuna
NPI 1750933594
$5,011.92
in general payments reported to CMS, 2019-2025
20 companies · $3,420 in 2025
The $3,420 reported for 2025 was more than what 97% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $200 · 2023: $471 · 2024: $921 · 2025: $3,420.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,413 · Travel and Lodging: $718 · Grant: $400 · Education: $281.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,413.00 |
| Travel and Lodging | $717.76 |
| Grant | $400.00 |
| Education | $281.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $2,032.37 | 2023-2025 | General - Therapies, General - Catheter, Avvigo Guidance System |
| Abiomed | $991.83 | 2022-2025 | Impella |
| Abbott Laboratories | $495.31 | 2024-2025 | Ensite, Pressurewire, Optis |
| Shockwave Medical, INC | $281.69 | 2024-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Penumbra, INC. | $236.00 | 2024-2025 | Indigo System, Ruby Coil |
| Pfizer INC. | $211.76 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $131.56 | 2022-2025 | Wainua |
| Novartis Pharmaceuticals Corporation | $126.95 | 2023-2025 | |
| Alnylam Pharmaceuticals INC. | $89.19 | 2024 | Amvuttra |
| E.R. Squibb & Sons, L.L.C. | $86.08 | 2023 | Camzyos |
| Heartflow, INC. | $64.18 | 2025 | |
| Irhythm Technologies, INC. | $59.23 | 2024 | Zio Xt Patch, Zio Monitor |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $48.97 | 2023-2025 | Lifevest |
| Philips North America LLC | $35.94 | 2025 | Ineb Devices |
| Bayer Healthcare Pharmaceuticals INC. | $27.31 | 2023 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biosense Webster, INC. | $25.72 | 2025 | Qdot Micro |
| Janssen Pharmaceuticals, INC | $20.48 | 2024 | Xarelto |
| Amgen INC. | $17.22 | 2023 | Repatha |
| Impulse Dynamics (USA) INC. | $17.06 | 2024 | Optimizer |
| Merck Sharp & Dohme LLC | $13.07 | 2023 | Verquvo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emmanuel Akuna listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.